NOL7 KO cell line available to order. Free of charge wild type control provided. Knockout achieved by using CRISPR/Cas9, 1 bp deletion in exon 1 and 1 bp insertion in exon 1.
Images
Key facts
- Cell type
- HEK-293T
- Species or organism
- Human
- Tissue
- Kidney
- Form
- Liquid
- Knockout validation
- Sanger Sequencing
- Mutation description
- Knockout achieved by using CRISPR/Cas9, 1 bp deletion in exon 1 and 1 bp insertion in exon 1
Alternative names
C6orf90, NOL7_HUMAN, NOP27, Nol7, Nucleolar protein 7, Nucleolar protein of 27 kDa, PQBP3, RARG-1, dJ223E5.2
Recommended products
NOL7 KO cell line available to order. Free of charge wild type control provided. Knockout achieved by using CRISPR/Cas9, 1 bp deletion in exon 1 and 1 bp insertion in exon 1.
Key facts
- Cell type
- HEK-293T
- Species or organism
- Human
- Tissue
- Kidney
- Form
- Liquid
- Knockout validation
- Sanger Sequencing
- Mutation description
- Knockout achieved by using CRISPR/Cas9, 1 bp deletion in exon 1 and 1 bp insertion in exon 1
- Concentration
Properties
- Gene name
- NOL7
- Gene editing type
- Knockout
- Gene editing method
- CRISPR technology
- Knockout validation
- Sanger Sequencing
Quality control
- STR analysis
- CSF1PO, D13S317, D7S820, D5S818, TH01, D16S539, TPOX
Cell culture
- Biosafety level
- EU: 2 US: 2
- Adherent/suspension
- Adherent
- Gender
- Female
Handling procedures
- Initial handling guidelines
Upon arrival, the vial should be stored in liquid nitrogen vapor phase and not at -80°C. Storage at -80°C may result in loss of viability.
1. Thaw the vial in 37°C water bath for approximately 1-2 minutes.
2. Transfer the cell suspension (0.8 mL) to a 15 mL/50 mL conical sterile polypropylene centrifuge tube containing 8.4 mL pre-warmed culture medium, wash vial with an additional 0.8 mL culture medium (total volume 10 mL) to collect remaining cells, and centrifuge at 201 x g (rcf) for 5 minutes at room temperature. 10 mL represents minimum recommended dilution. 20 mL represents maximum recommended dilution.
3. Resuspend the cell pellet in 5 mL pre-warmed culture medium and count using a haemocytometer or alternative cell counting method seed all remaining cells into a T25.
4. Incubate the culture at 37°C incubator with 5% CO2. Check the culture one day after revival and continue to check until 80% confluent. Media change can be given if needed.
5. Once confluent passage into an appropriate flask at a density of 2x104 cells/cm2. Seeding density is given as a guide only and should be scaled to align with individual lab schedules. Cultures should be monitored daily.- Subculture guidelines
- All seeding densities should be based on cell counts gained by established methods.
- A guide seeding density of 2x104 cells/cm2 is recommended.
- Cells should be passaged when they have achieved 80-90% confluence.
- Culture medium
- DMEM (High Glucose) + 10% FBS
- Cryopreservation medium
- Cell Freezing Medium-DMSO Serum free media, contains 8.7% DMSO in MEM supplemented with methyl cellulose.
Storage
- Shipped at conditions
- Dry Ice
- Appropriate short-term storage conditions
- -196°C
- Appropriate long-term storage conditions
- -196°C
Notes
We will provide viable cells that proliferate on revival.
This product is subject to limited use licenses from The Broad Institute, ERS Genomics Limited and Sigma-Aldrich Co. LLC, and is developed with patented technology. For full details of the licenses and patents please refer to our limited use license and patent pages.
Supplementary info
- This supplementary information is collated from multiple sources and compiled automatically.
- Activity summary
Nucleolar Protein 7 commonly known as NOL7 is a human protein with a mass of approximately 26 kDa. NOL7 is mainly found in the nucleolus of cells which indicates its potential role in ribosomal RNA processing or ribosome assembly. As a nucleolar protein NOL7 expression occurs across various tissues providing a widespread substrate for its biological functions.
- Biological function summary
The role of NOL7 involves regulation of cellular growth and proliferation. It acts potentially as a tumor suppressor contributing to the control of angiogenesis and maintaining cell cycle progression. NOL7 forms part of larger nucleolar complexes participating in ribonucleoprotein formation needed for effective cellular operations. Its presence and activity help maintain normal cellular and tissue homeostasis.
- Pathways
NOL7 influences pathways involved in angiogenesis and cellular proliferation. It interacts directly with certain key proteins like Vascular Endothelial Growth Factor (VEGF) inhibiting its excessive expression and therefore functioning as part of the angiogenic pathway. NOL7’s activity aids the maintenance of balanced angiogenic signals helping to regulate vascular development within tissues.
- Associated diseases and disorders
The expression and functionality of NOL7 have connections to cancer and cardiovascular diseases. NOL7’s potential tumor-suppressive properties relate it to various cancer types where its dysregulation may contribute to uncontrolled cell growth. In the context of cardiovascular disease NOL7 interacts with VEGF playing a role in the pathological neovascularization processes. Efforts to understand NOL7 could provide insights into new therapeutic strategies for diseases involving abnormal angiogenesis.
Product promise
We are dedicated to supporting your work with high quality reagents and we are here for you every step of the way should you need us.
In the unlikely event of one of our products not working as expected, you are covered by our product promise.
Full details and terms and conditions can be found here:
Terms & Conditions.
2 product images
Sanger Sequencing - Human NOL7 knockout HEK-293T cell line (ab266638)
Allele-2: 1 bp insertion in exon 1.
Sanger Sequencing - Human NOL7 knockout HEK-293T cell line (ab266638)
Allele-1: 1 bp deletion in exon 1
Downloads
Product protocols
- Visit the general protocols
- Visit troubleshooting
Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.
For licensing inquiries, please contact partnerships@abcam.com